AUPQ761200A0 - Compositions and methods for treatment of mucosal infections - Google Patents

Compositions and methods for treatment of mucosal infections

Info

Publication number
AUPQ761200A0
AUPQ761200A0 AUPQ7612A AUPQ761200A AUPQ761200A0 AU PQ761200 A0 AUPQ761200 A0 AU PQ761200A0 AU PQ7612 A AUPQ7612 A AU PQ7612A AU PQ761200 A AUPQ761200 A AU PQ761200A AU PQ761200 A0 AUPQ761200 A0 AU PQ761200A0
Authority
AU
Australia
Prior art keywords
methods
compositions
treatment
mucosal infections
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPQ7612A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hunter Immunology Pty Ltd
Original Assignee
PNEUMOBIOTICS Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PNEUMOBIOTICS Pty Ltd filed Critical PNEUMOBIOTICS Pty Ltd
Priority to AUPQ7612A priority Critical patent/AUPQ761200A0/en
Publication of AUPQ761200A0 publication Critical patent/AUPQ761200A0/en
Priority to BR0110971-5A priority patent/BR0110971A/pt
Priority to AT01931225T priority patent/ATE535284T1/de
Priority to KR1020027015631A priority patent/KR20030019389A/ko
Priority to AU5806001A priority patent/AU5806001A/xx
Priority to US10/276,829 priority patent/US8637051B2/en
Priority to PCT/AU2001/000588 priority patent/WO2001087332A1/en
Priority to CN01811367A priority patent/CN1437480A/zh
Priority to JP2001583799A priority patent/JP5567756B2/ja
Priority to CA2409813A priority patent/CA2409813C/en
Priority to AU2001258060A priority patent/AU2001258060B2/en
Priority to EP01931225A priority patent/EP1305042B1/en
Assigned to HUNTER IMMUNOLOGY LIMITED reassignment HUNTER IMMUNOLOGY LIMITED Assignment by Applicant under S 113 Assignors: PNEUMOBIOTICS PTY LTD
Priority to JP2012080832A priority patent/JP2012153706A/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AUPQ7612A 2000-05-19 2000-05-19 Compositions and methods for treatment of mucosal infections Abandoned AUPQ761200A0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AUPQ7612A AUPQ761200A0 (en) 2000-05-19 2000-05-19 Compositions and methods for treatment of mucosal infections
EP01931225A EP1305042B1 (en) 2000-05-19 2001-05-21 Compositions comprising non-typable Haemophilus influenzae (NTHI) and probiotic bacteria for the treatment of mucosal infections caused by NTHI
PCT/AU2001/000588 WO2001087332A1 (en) 2000-05-19 2001-05-21 Compositions and methods for treatment of mucosal infections
JP2001583799A JP5567756B2 (ja) 2000-05-19 2001-05-21 粘膜感染症の処置のための組成物および方法
KR1020027015631A KR20030019389A (ko) 2000-05-19 2001-05-21 점막감염의 치료 조성물 및 방법
AU5806001A AU5806001A (en) 2000-05-19 2001-05-21 Compositions and methods for treatment of mucosal infections
US10/276,829 US8637051B2 (en) 2000-05-19 2001-05-21 Compositions and methods for treatment of mucosal infections
BR0110971-5A BR0110971A (pt) 2000-05-19 2001-05-21 Composições e métodos para tratamento de infecções das mucosas
CN01811367A CN1437480A (zh) 2000-05-19 2001-05-21 治疗粘膜感染的组合物和方法
AT01931225T ATE535284T1 (de) 2000-05-19 2001-05-21 Zusammensetzungen die non-typable haemophilus influenzae (nthi) und probiotische bakterien enthalten zur behandlung von nthi verursachten schleimhautinfektionen
CA2409813A CA2409813C (en) 2000-05-19 2001-05-21 Compositions and methods for treatment of mucosal infections
AU2001258060A AU2001258060B2 (en) 2000-05-19 2001-05-21 Compositions and methods for treatment of mucosal infections
JP2012080832A JP2012153706A (ja) 2000-05-19 2012-03-30 粘膜感染症の処置のための組成物および方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPQ7612A AUPQ761200A0 (en) 2000-05-19 2000-05-19 Compositions and methods for treatment of mucosal infections

Publications (1)

Publication Number Publication Date
AUPQ761200A0 true AUPQ761200A0 (en) 2000-06-15

Family

ID=3821690

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPQ7612A Abandoned AUPQ761200A0 (en) 2000-05-19 2000-05-19 Compositions and methods for treatment of mucosal infections

Country Status (10)

Country Link
US (1) US8637051B2 (enExample)
EP (1) EP1305042B1 (enExample)
JP (2) JP5567756B2 (enExample)
KR (1) KR20030019389A (enExample)
CN (1) CN1437480A (enExample)
AT (1) ATE535284T1 (enExample)
AU (1) AUPQ761200A0 (enExample)
BR (1) BR0110971A (enExample)
CA (1) CA2409813C (enExample)
WO (1) WO2001087332A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
WO2005077409A1 (en) * 2004-02-18 2005-08-25 The University Of Newcastle Research Associates Limited A vaccine formulated for administration to mucosa of the lungs
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
EP1793848A4 (en) * 2004-08-17 2008-06-11 Hunter Immunology Ltd METHOD OF DETERMINING A DOSAGE FOR ORAL INACTIVE VACCINE
ATE526978T1 (de) 2004-08-17 2011-10-15 Hunter Immunology Ltd Verfahren zur herstellung von oral abgetöteten vakzinen
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US8857659B2 (en) 2010-03-18 2014-10-14 Eveready Battery Company, Inc. Button cell battery dispenser package
EP2585094B1 (en) * 2010-06-25 2018-08-01 INSERM - Institut National de la Santé et de la Recherche Médicale Flagellin polypeptide as tlr5 agonist for use in the treatment of respiratory tract infections
US20140275420A1 (en) 2011-08-22 2014-09-18 Carnegie Mellon University Atom transfer radical polymerization under biologically compatible conditions
CA3254723A1 (en) * 2014-05-02 2025-04-15 Qu Biologics Inc ANTIMICROBIAL IMMUNOMODULATION
US9982070B2 (en) 2015-01-12 2018-05-29 Carnegie Mellon University Aqueous ATRP in the presence of an activator regenerator
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
AU2021252164A1 (en) 2020-04-09 2022-12-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
CN111529703B (zh) * 2020-06-17 2023-09-15 湖南循天然营养有限公司 一种组合物及其制备方法与在制备免疫佐剂中的应用
WO2024234034A1 (en) * 2023-05-12 2024-11-21 Biomune Pty Ltd Compositions and methods for preventative treatments for mucosal associated ailments

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA907737B (en) * 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration
US6231870B1 (en) * 1995-06-02 2001-05-15 Uab Research Foundation Oral administration of pneumoccal antigens
JPH0680575A (ja) * 1991-03-05 1994-03-22 Meiji Milk Prod Co Ltd 経口免疫賦活剤
ES2262181T3 (es) 1996-05-31 2006-11-16 National University Of Ireland, Maynooth Il-12 como adyuvante en la vacuna contra la especie bordetella pertussis.
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
WO1999012416A1 (en) * 1997-09-09 1999-03-18 The Trustees Of Columbia University In The City Of New York T-independent conjugate-vaccines
US6153182A (en) 1997-12-19 2000-11-28 Uab Research Foundation Lymphotactin as an adjuvant
PL341697A1 (en) 1997-12-23 2001-04-23 Genesis Res & Dev Corp Ltd Compositions derived from mycobacterium vaccae and methods of using them
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
GB9801870D0 (en) * 1998-01-28 1998-03-25 Raby Limited Vaccine composition
DE69942214D1 (de) 1998-02-05 2010-05-12 Glaxosmithkline Biolog Sa Verfahren zur Reinigung oder Herstellung der MAGE Protein
SE9800615D0 (sv) * 1998-02-27 1998-02-27 Ingvar Sjoeholm Mucosal microparticle conjugate vaccine
US5985264A (en) * 1998-03-05 1999-11-16 The Medical College Of Ohio IL-12 Stimulation of Neonatal immunity
CN1298307A (zh) 1998-03-05 2001-06-06 俄亥俄医学院 通过鼻内接种il－12加强免疫性
FR2776521B1 (fr) * 1998-03-27 2000-12-15 Pf Medicament Utilisation de conjugues p40 actifs par voie nasale
EP1087788A1 (fr) * 1998-06-26 2001-04-04 Aventis Pasteur Immunisation a ciblage mucosal
AR020102A1 (es) 1998-07-30 2002-04-10 Ucb Sa Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
US7223398B1 (en) * 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US20020044926A1 (en) * 1999-12-10 2002-04-18 Gregor Reid Oral administration of lactobacillus for the treatment and prevention of urogenital infection
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
EP1303300B1 (en) * 2000-06-19 2010-08-11 Hunter Immunology Limited Compositions and methods for treatment of candidiasis
NZ523995A (en) * 2000-08-08 2005-03-24 Genesis Res & Dev Corp Ltd Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them

Also Published As

Publication number Publication date
CA2409813A1 (en) 2001-11-22
BR0110971A (pt) 2005-04-05
JP2003533489A (ja) 2003-11-11
EP1305042A4 (en) 2005-02-02
WO2001087332A1 (en) 2001-11-22
EP1305042A1 (en) 2003-05-02
CN1437480A (zh) 2003-08-20
JP2012153706A (ja) 2012-08-16
EP1305042B1 (en) 2011-11-30
ATE535284T1 (de) 2011-12-15
US20040057965A1 (en) 2004-03-25
CA2409813C (en) 2013-11-12
JP5567756B2 (ja) 2014-08-06
US8637051B2 (en) 2014-01-28
KR20030019389A (ko) 2003-03-06

Similar Documents

Publication Publication Date Title
AUPQ761200A0 (en) Compositions and methods for treatment of mucosal infections
WO2003099110A3 (en) Herbs and herbal combinations useful for the treatment of microbial infections
MXPA04005865A (es) Suministro de aminoglucosidos a los pulmones.
AU7144901A (en) Human papilloma virus treatment
GB0101577D0 (en) Compounds
AU4358801A (en) Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
WO2002009746A3 (en) Vaccines comprising outer membrane vesciles from gram negative bacteria
SE0102315D0 (sv) Compounds
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
MXPA04003796A (es) Tioacetamidas sustituidas.
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
WO2001082788A3 (en) Compounds and methods for the treatment and prevention of bacterial infection
EP1471936A4 (en) HIV VACCINE AND METHOD OF USE
WO2002034773A3 (en) Streptococcal genes
AU2003270498A1 (en) Topical veterinary compositions and methods for the treatment and prevention of infection
WO2004026260A3 (en) Prophylactic and therapeutic hiv aptamers
WO2002060936A3 (en) Vaccine and compositions for the prevention and treatment of neisserial infections
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
AU2002341207A1 (en) Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
AU2002327531A1 (en) Therapeutic compositions and methods for treating viral infection
WO2002078717A3 (en) Compositions and methods for reducing rna virus pathogenicity
AU2003216927A1 (en) Novel therapeutic composition for the prevention and treatment of hiv-1 infection in humans
WO2003053959A8 (de) Heterocyclylaminocarbo nyluracile

Legal Events

Date Code Title Description
NAA1 Application designating australia and claiming priority from australian document

Ref document number: 5806001

Country of ref document: AU